Drug news

NICE now supports Tecentriq to treat Bladder Cancer. Roche.

Read time: 1 mins

Last updated:14th Nov 2017

Published:2nd Nov 2017

Source: Pharmawand

The National Institute for Health and Care Excellence (NICE) has now recommended that Tecentriq (atezolizumab) from Roche may be used within the Cancer Drugs Fund to treat patients with untreated urothelial cancer (bladder cancer) whose cancer cannot be treated by cisplatin-based chemotherapy.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation to change to marketing authorisation of Triumeq (abacavir sulfate / dolutegravir sodium / lamivudine) to treat HIV infections.-ViiV HealthCare

1 mins

Drug news

CHMP positive recommendation to change the marketing authorisation of Sirturo (bedaquiline) in patients with pulmonary tuberculosis.- Jansssen- Cilag (J&J)

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sirturo (bedaquiline). The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV.

1 min

Drug news

CHMP positive recommendation to extend the marketing authorisation of Alecensa (alectinib hydrochloride).- Roche.

1 min

See all news